Abstract
Anemia occurs with high incidence in patients affected by chronic renal failure (CRF) [1], Many factors have been described as being responsible for the anemic status in these patients [2-5]. Erythropoietin deficiency seems to be the main cause of anemia in CRF [6]. Blood transfusions are frequently needed to counteract this complication, with the risk of hepatitis, AIDS, iron overload, and sensitization of hystocompatibility antigens, with reduction in the success probability rates for renal transplantation [7]. Nowadays, the possibility of having sufficient amounts of human erythropoietin, produced by DNA-recombinant methods (rHuEPO) [8, 9] has made the therapeutic use of this compound available for the treatment of anemia in CRF patients [7, 10-14].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
